{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:06:59Z","timestamp":1793743619010,"version":"4.6.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Giant cell myocarditis (GCM) is a rare but devastating inflammatory cardiac disease characterized by rapid hemodynamic deterioration, malignant arrhythmias, and high rates of death or heart transplantation. Without immunosuppressive treatment, median transplant-free survival is approximately three months. Current evidence identifies GCM as a predominantly T cell\u2013mediated autoimmune disorder driven by a breakdown of immune tolerance, with contributions from macrophage-derived multinucleated giant cells and neutrophil extracellular trap formation. Viral infections and environmental factors have been implicated as potential triggers. GCM typically affects middle-aged adults, with concomitant non-cardiac autoimmune diseases present in approximately 20% of cases. Early diagnosis remains challenging, as clinical presentation and imaging findings are nonspecific and overlap considerably with cardiac sarcoidosis. Endomyocardial biopsy continues to represent the diagnostic gold standard, with a sensitivity of 85%, while cardiac biomarkers including cardiac troponins and NT-proBNP provide important prognostic information. Cardiac magnetic resonance imaging and FDG-PET contribute to the diagnostic workup but cannot reliably differentiate GCM from cardiac sarcoidosis. Management requires prompt initiation of combination immunosuppressive therapy\u2014typically corticosteroids combined with T cell\u2013targeted agents such as cyclosporine and azathioprine or tacrolimus and mycophenolate mofetil, which has substantially improved survival in contemporary registries. Mechanical circulatory support and heart transplantation are frequently required for refractory cases. Given the high arrhythmic burden, systematic evaluation for implantable cardioverter-defibrillator placement is recommended. This review provides a comprehensive overview of the pathogenesis, diagnosis, and current management of GCM and highlights priorities for future research, including noninvasive diagnostic tools and standardized treatment protocols.<\/jats:p>","DOI":"10.1007\/s10741-026-10668-6","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T02:26:14Z","timestamp":1787279174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Giant cell myocarditis: from immune pathogenesis to contemporary management"],"prefix":"10.1007","volume":"31","author":[{"given":"Ivan","family":"Vosko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wallner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"1","key":"10668_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/bf01995636","volume":"182","author":"S Saltykow","year":"1905","unstructured":"Saltykow S (1905) \u00dcber diffuse Myokarditis. Virchows Archiv f\u00fcr Pathologische Anatomie und Physiologie und f\u00fcr Klinische Medizin 182(1):1\u201339. https:\/\/doi.org\/10.1007\/bf01995636","journal-title":"Virchows Archiv f\u00fcr Pathologische Anatomie und Physiologie und f\u00fcr Klinische Medizin"},{"issue":"32","key":"10668_CR2","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/eurheartj\/ehu101","volume":"35","author":"D Lassner","year":"2014","unstructured":"Lassner D, Kuhl U, Siegismund CS, Rohde M, Elezkurtaj S, Escher F et al (2014) Improved diagnosis of idiopathic giant cell myocarditis and cardiac sarcoidosis by myocardial gene expression profiling. Eur Heart J 35(32):2186\u20132195. https:\/\/doi.org\/10.1093\/eurheartj\/ehu101","journal-title":"Eur Heart J"},{"issue":"6","key":"10668_CR3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s10741-012-9358-3","volume":"18","author":"LA Blauwet","year":"2013","unstructured":"Blauwet LA, Cooper LT (2013) Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev 18(6):733\u2013746. https:\/\/doi.org\/10.1007\/s10741-012-9358-3","journal-title":"Heart Fail Rev"},{"issue":"8","key":"10668_CR4","doi-asserted-by":"publisher","first-page":"e6196","DOI":"10.1002\/ccr3.6196","volume":"10","author":"A Amiri","year":"2022","unstructured":"Amiri A, Houshmand G, Taghavi S, Kamali M, Faraji M, Naderi N (2022) Giant cell myocarditis following COVID-19 successfully treated by immunosuppressive therapy. Clin Case Rep 10(8):e6196. https:\/\/doi.org\/10.1002\/ccr3.6196","journal-title":"Clin Case Rep"},{"issue":"3","key":"10668_CR5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/CIRCRESAHA.121.319317","volume":"129","author":"K Amancherla","year":"2021","unstructured":"Amancherla K, Qin J, Wang Y, Axelrod ML, Balko JM, Schlendorf KH et al (2021) RNA-Sequencing reveals a distinct transcriptomic signature for giant cell myocarditis and identifies novel druggable targets. Circ Res 129(3):451\u2013453. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.319317","journal-title":"Circ Res"},{"issue":"8","key":"10668_CR6","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.4049\/jimmunol.176.8.4748","volume":"176","author":"M Ono","year":"2006","unstructured":"Ono M, Shimizu J, Miyachi Y, Sakaguchi S (2006) Control of autoimmune myocarditis and multiorgan inflammation by glucocorticoid-induced TNF receptor family-related protein(high), Foxp3-expressing CD25\u2009+\u2009and CD25- regulatory T cells. J Immunol 176(8):4748\u20134756. https:\/\/doi.org\/10.4049\/jimmunol.176.8.4748","journal-title":"J Immunol"},{"issue":"7","key":"10668_CR7","doi-asserted-by":"publisher","first-page":"107162","DOI":"10.1016\/j.isci.2023.107162","volume":"26","author":"Z Hu","year":"2023","unstructured":"Hu Z, Hua X, Mo X, Chang Y, Chen X, Xu Z et al (2023) Inhibition of NETosis via PAD4 alleviated inflammation in giant cell myocarditis. iScience 26(7):107162. https:\/\/doi.org\/10.1016\/j.isci.2023.107162","journal-title":"iScience"},{"issue":"12","key":"10668_CR8","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1253\/jcj.50.1288","volume":"50","author":"S Wakafuji","year":"1986","unstructured":"Wakafuji S, Okada R (1986) Twenty year autopsy statistics of myocarditis incidence in Japan. Jpn Circ J 50(12):1288\u20131293. https:\/\/doi.org\/10.1253\/jcj.50.1288","journal-title":"Jpn Circ J"},{"issue":"8","key":"10668_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.jacc.2020.11.074","volume":"77","author":"V Bang","year":"2021","unstructured":"Bang V, Ganatra S, Shah SP, Dani SS, Neilan TG, Thavendiranathan P et al (2021) Management of Patients With Giant Cell Myocarditis: JACC Review Topic of the Week. J Am Coll Cardiol 77(8):1122\u20131134. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.074","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10668_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12872-022-02639-0","volume":"22","author":"E Bobbio","year":"2022","unstructured":"Bobbio E, Hjalmarsson C, Bjorkenstam M, Polte CL, Oldfors A, Lindstrom U et al (2022) Diagnosis, management, and outcome of cardiac sarcoidosis and giant cell myocarditis: A Swedish single center experience. BMC Cardiovasc Disord 22(1):192. https:\/\/doi.org\/10.1186\/s12872-022-02639-0","journal-title":"BMC Cardiovasc Disord"},{"issue":"26","key":"10668_CR11","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJM199706263362603","volume":"336","author":"LT Cooper Jr","year":"1997","unstructured":"Cooper LT Jr., Berry GJ, Shabetai R (1997) Idiopathic giant-cell myocarditis\u2013natural history and treatment. Multicenter giant cell myocarditis study group investigators. N Engl J Med 336(26):1860\u20131866. https:\/\/doi.org\/10.1056\/NEJM199706263362603","journal-title":"N Engl J Med"},{"issue":"12","key":"10668_CR12","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1002\/ejhf.606","volume":"18","author":"K Ekstrom","year":"2016","unstructured":"Ekstrom K, Lehtonen J, Kandolin R, Raisanen-Sokolowski A, Salmenkivi K, Kupari M (2016) Long-term outcome and its predictors in giant cell myocarditis. Eur J Heart Fail 18(12):1452\u20131458. https:\/\/doi.org\/10.1002\/ejhf.606","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10668_CR13","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.amjcard.2015.03.023","volume":"115","author":"JJ Maleszewski","year":"2015","unstructured":"Maleszewski JJ, Orellana VM, Hodge DO, Kuhl U, Schultheiss HP, Cooper LT (2015) Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am J Cardiol 115(12):1733\u20131738. https:\/\/doi.org\/10.1016\/j.amjcard.2015.03.023","journal-title":"Am J Cardiol"},{"issue":"3","key":"10668_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/s1053-2498(00)00314-4","volume":"20","author":"RL Scott","year":"2001","unstructured":"Scott RL, Ratliff NB, Starling RC, Young JB (2001) Recurrence of giant cell myocarditis in cardiac allograft. J Heart Lung Transpl 20(3):375\u2013380. https:\/\/doi.org\/10.1016\/s1053-2498(00)00314-4","journal-title":"J Heart Lung Transpl"},{"key":"10668_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.amjcard.2023.08.005","volume":"207","author":"AP Stein","year":"2023","unstructured":"Stein AP, Stewart BD, Patel DC, Al-Ani M, Vilaro J, Aranda JM Jr. et al (2023) Recurrent cardiac sarcoidosis and giant cell myocarditis after heart transplant: A case report and systematic literature review. Am J Cardiol 207:271\u2013279. https:\/\/doi.org\/10.1016\/j.amjcard.2023.08.005","journal-title":"Am J Cardiol"},{"issue":"1","key":"10668_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1161\/CIRCHEARTFAILURE.112.969261","volume":"6","author":"R Kandolin","year":"2013","unstructured":"Kandolin R, Lehtonen J, Salmenkivi K, Raisanen-Sokolowski A, Lommi J, Kupari M (2013) Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail 6(1):15\u201322. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.112.969261","journal-title":"Circ Heart Fail"},{"issue":"7","key":"10668_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.cardfail.2015.12.022","volume":"22","author":"NA Gilotra","year":"2016","unstructured":"Gilotra NA, Minkove N, Bennett MK, Tedford RJ, Steenbergen C, Judge DP et al (2016) Lack of relationship between serum cardiac troponin I level and giant cell myocarditis diagnosis and outcomes. J Card Fail 22(7):583\u2013585. https:\/\/doi.org\/10.1016\/j.cardfail.2015.12.022","journal-title":"J Card Fail"},{"issue":"11","key":"10668_CR18","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.amjcard.2008.07.041","volume":"102","author":"LT Cooper Jr","year":"2008","unstructured":"Cooper LT Jr., Hare JM, Tazelaar HD, Edwards WD, Starling RC, Deng MC et al (2008) Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 102(11):1535\u20131539. https:\/\/doi.org\/10.1016\/j.amjcard.2008.07.041","journal-title":"Am J Cardiol"},{"key":"10668_CR19","doi-asserted-by":"publisher","unstructured":"Ekstrom K, Lehtonen J, Kandolin R, Raisanen-Sokolowski A, Salmenkivi K, Kupari M, Incidence (2016) risk factors, and outcome of life-threatening ventricular arrhythmias in giant cell myocarditis. Circ Arrhythm Electrophysiol 9(12). https:\/\/doi.org\/10.1161\/CIRCEP.116.004559","DOI":"10.1161\/CIRCEP.116.004559"},{"issue":"6","key":"10668_CR20","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s10554-023-02827-9","volume":"39","author":"C Meindl","year":"2023","unstructured":"Meindl C, Paulus M, Poschenrieder F, Hamer OW, Zeman F, Maier LS et al (2023) Left atrial strain parameters derived by echocardiography are impaired in patients with acute myocarditis and preserved systolic left ventricular function. Int J Cardiovasc Imaging 39(6):1157\u20131165. https:\/\/doi.org\/10.1007\/s10554-023-02827-9","journal-title":"Int J Cardiovasc Imaging"},{"issue":"4","key":"10668_CR21","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/ehjci\/jeac265","volume":"24","author":"P Poyhonen","year":"2023","unstructured":"Poyhonen P, Nordenswan HK, Lehtonen J, Syvaranta S, Shenoy C, Kupari M (2023) Cardiac magnetic resonance in giant cell myocarditis: A matched comparison with cardiac sarcoidosis. Eur Heart J Cardiovasc Imaging 24(4):404\u2013412. https:\/\/doi.org\/10.1093\/ehjci\/jeac265","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"Suppl C","key":"10668_CR22","doi-asserted-by":"publisher","first-page":"C130","DOI":"10.1093\/eurheartjsupp\/suad015","volume":"25","author":"GD Aquaro","year":"2023","unstructured":"Aquaro GD, De Gori C, Faggioni L, Parisella ML, Cioni D, Lencioni R et al (2023) Diagnostic and prognostic role of late gadolinium enhancement in cardiomyopathies. Eur Heart J Suppl 25(Suppl C):C130\u2013C6. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad015","journal-title":"Eur Heart J Suppl"},{"issue":"1","key":"10668_CR23","doi-asserted-by":"publisher","first-page":"e011492","DOI":"10.1161\/CIRCIMAGING.120.011492","volume":"14","author":"G Georgiopoulos","year":"2021","unstructured":"Georgiopoulos G, Figliozzi S, Sanguineti F, Aquaro GD, di Bella G, Stamatelopoulos K et al (2021) Prognostic impact of late gadolinium enhancement by cardiovascular magnetic resonance in myocarditis: A systematic review and meta-analysis. Circ Cardiovasc Imaging 14(1):e011492. https:\/\/doi.org\/10.1161\/CIRCIMAGING.120.011492","journal-title":"Circ Cardiovasc Imaging"},{"issue":"30","key":"10668_CR24","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1093\/eurheartj\/ehae356","volume":"45","author":"R Sharma","year":"2024","unstructured":"Sharma R, Kouranos V, Cooper LT, Metra M, Ristic A, Heidecker B et al (2024) Management of cardiac sarcoidosis. Eur Heart J 45(30):2697\u20132726. https:\/\/doi.org\/10.1093\/eurheartj\/ehae356","journal-title":"Eur Heart J"},{"issue":"3","key":"10668_CR25","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1002\/ehf2.13276","volume":"8","author":"S Yang","year":"2021","unstructured":"Yang S, Chen X, Li J, Sun Y, Song J, Wang H et al (2021) Late gadolinium enhancement characteristics in giant cell myocarditis. ESC Heart Fail 8(3):2320\u20132327. https:\/\/doi.org\/10.1002\/ehf2.13276","journal-title":"ESC Heart Fail"},{"issue":"17","key":"10668_CR26","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1093\/eurheartj\/ehad067","volume":"44","author":"J Lehtonen","year":"2023","unstructured":"Lehtonen J, Uusitalo V, Poyhonen P, Mayranpaa MI, Kupari M (2023) Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis. Eur Heart J 44(17):1495\u20131510. https:\/\/doi.org\/10.1093\/eurheartj\/ehad067","journal-title":"Eur Heart J"},{"key":"10668_CR27","doi-asserted-by":"publisher","first-page":"131143","DOI":"10.1016\/j.ijcard.2023.131143","volume":"387","author":"E Bobbio","year":"2023","unstructured":"Bobbio E, Bollano E, Oldfors A, Hedner H, Bjorkenstam M, Svedlund S et al (2023) Phenotyping of giant cell myocarditis versus cardiac sarcoidosis using cardiovascular magnetic resonance. Int J Cardiol 387:131143. https:\/\/doi.org\/10.1016\/j.ijcard.2023.131143","journal-title":"Int J Cardiol"},{"issue":"40","key":"10668_CR28","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1093\/eurheartj\/ehaf192","volume":"46","author":"J Schulz-Menger","year":"2025","unstructured":"Schulz-Menger J, Collini V, Groschel J, Adler Y, Brucato A, Christian V et al (2025) 2025 ESC Guidelines for the management of myocarditis and pericarditis. Eur Heart J 46(40):3952\u20134041. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf192","journal-title":"Eur Heart J"},{"issue":"48","key":"10668_CR29","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1093\/eurheartj\/ehad707","volume":"44","author":"F Huang","year":"2023","unstructured":"Huang F, Ammirati E, Ponnaiah M, Montero S, Raimbault V, Abrams D et al (2023) Fulminant myocarditis proven by early biopsy and outcomes. Eur Heart J 44(48):5110\u20135124. https:\/\/doi.org\/10.1093\/eurheartj\/ehad707","journal-title":"Eur Heart J"},{"issue":"9","key":"10668_CR30","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1161\/CIRCULATIONAHA.109.924167","volume":"122","author":"A Yilmaz","year":"2010","unstructured":"Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A et al (2010) Comparative evaluation of left and right ventricular endomyocardial biopsy: Differences in complication rate and diagnostic performance. Circulation 122(9):900\u2013909. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.924167","journal-title":"Circulation"},{"issue":"2","key":"10668_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1054\/jcaf.2002.32196","volume":"8","author":"RC Shields","year":"2002","unstructured":"Shields RC, Tazelaar HD, Berry GJ, Cooper LT Jr (2002) The role of right ventricular endomyocardial biopsy for idiopathic giant cell myocarditis. J Card Fail 8(2):74\u201378. https:\/\/doi.org\/10.1054\/jcaf.2002.32196","journal-title":"J Card Fail"},{"issue":"2","key":"10668_CR32","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/s0735-1097(02)02715-8","volume":"41","author":"Y Okura","year":"2003","unstructured":"Okura Y, Dec GW, Hare JM, Kodama M, Berry GJ, Tazelaar HD et al (2003) A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol 41(2):322\u2013329. https:\/\/doi.org\/10.1016\/s0735-1097(02)02715-8","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10668_CR33","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/jama.2023.3371","volume":"329","author":"E Ammirati","year":"2023","unstructured":"Ammirati E, Moslehi JJ (2023) Diagnosis and Treatment of Acute Myocarditis: A Review. JAMA 329(13):1098\u20131113. https:\/\/doi.org\/10.1001\/jama.2023.3371","journal-title":"JAMA"},{"issue":"17","key":"10668_CR34","doi-asserted-by":"publisher","first-page":"103859","DOI":"10.1016\/j.jaccas.2025.103859","volume":"30","author":"SH Byer","year":"2025","unstructured":"Byer SH, Mortada I, Mhanna M, Walsh ME, Arustamyan M, Pachariyanon P et al (2025) Giant cell myocarditis presenting with cardiogenic shock: Diagnostic and therapeutic challenges. JACC Case Rep 30(17):103859. https:\/\/doi.org\/10.1016\/j.jaccas.2025.103859","journal-title":"JACC Case Rep"},{"issue":"6","key":"10668_CR35","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jccase.2023.01.009","volume":"27","author":"H Tsuchiya","year":"2023","unstructured":"Tsuchiya H, Kashimura T, Washiyama Y, Kumaki T, Watanabe M, Kase M et al (2023) A case of giant cell myocarditis mimicking cardiac sarcoidosis successfully maintained by prednisolone and tacrolimus. J Cardiol Cases 27(6):258\u2013261. https:\/\/doi.org\/10.1016\/j.jccase.2023.01.009","journal-title":"J Cardiol Cases"},{"issue":"19","key":"10668_CR36","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.2169\/internalmedicine.9112-21","volume":"61","author":"T Funaki","year":"2022","unstructured":"Funaki T, Saji M, Murai T, Higuchi R, Nanasato M, Isobe M (2022) Combination Immunosuppressive Therapy for Giant Cell Myocarditis. Intern Med 61(19):2895\u20132898. https:\/\/doi.org\/10.2169\/internalmedicine.9112-21","journal-title":"Intern Med"},{"key":"10668_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ijcard.2017.10.053","volume":"253","author":"S Montero","year":"2018","unstructured":"Montero S, Aissaoui N, Tadie JM, Bizouarn P, Scherrer V, Persichini R et al (2018) Fulminant giant-cell myocarditis on mechanical circulatory support: Management and outcomes of a French multicentre cohort. Int J Cardiol 253:105\u2013112. https:\/\/doi.org\/10.1016\/j.ijcard.2017.10.053","journal-title":"Int J Cardiol"},{"key":"10668_CR38","doi-asserted-by":"publisher","unstructured":"Kraus M, Grewal S, Boehmer JP (2025) Impella 5.5 as a bridge to cardiac recovery in idiopathic giant cell myocarditis. J Am Coll Cardiol 85(12). https:\/\/doi.org\/10.1016\/s0735-1097(25)03951-8","DOI":"10.1016\/s0735-1097(25)03951-8"},{"key":"10668_CR39","doi-asserted-by":"publisher","unstructured":"Lenz M, Krychtiuk KA, Zilberszac R, Heinz G, Riebandt J, Speidl WS (2024) Mechanical circulatory support systems in fulminant myocarditis: Recent advances and outlook. J Clin Med 13(5). https:\/\/doi.org\/10.3390\/jcm13051197","DOI":"10.3390\/jcm13051197"},{"issue":"7","key":"10668_CR40","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.cardfail.2017.04.015","volume":"23","author":"CA Elamm","year":"2017","unstructured":"Elamm CA, Al-Kindi SG, Bianco CM, Dhakal BP, Oliveira GH (2017) Heart transplantation in giant cell myocarditis: Analysis of the united network for organ sharing registry. J Card Fail 23(7):566\u2013569. https:\/\/doi.org\/10.1016\/j.cardfail.2017.04.015","journal-title":"J Card Fail"},{"key":"10668_CR41","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ijcard.2016.02.060","volume":"209","author":"D Heinzmann","year":"2016","unstructured":"Heinzmann D, Schibilsky D, Gramlich M, Klingel K, Kandolf R, Rosenberger P et al (2016) Ablation of an electrical storm in a patient with giant cell myocarditis using continuous flow left ventricular assist device and percutaneous right ventricular assist device. Int J Cardiol 209:84\u201386. https:\/\/doi.org\/10.1016\/j.ijcard.2016.02.060","journal-title":"Int J Cardiol"},{"issue":"11","key":"10668_CR42","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/j.1540-8167.2008.01177.x","volume":"19","author":"VS Chauhan","year":"2008","unstructured":"Chauhan VS, Hameedullah I, Nanthakumar K, Downar E (2008) Epicardial catheter ablation of incessant ventricular tachycardia in giant cell myocarditis. J Cardiovasc Electrophysiol 19(11):1219. https:\/\/doi.org\/10.1111\/j.1540-8167.2008.01177.x","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"40","key":"10668_CR43","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","volume":"43","author":"K Zeppenfeld","year":"2022","unstructured":"Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA et al (2022) 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 43(40):3997\u20134126. https:\/\/doi.org\/10.1093\/eurheartj\/ehac262","journal-title":"Eur Heart J"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10668-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10668-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10668-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T02:26:16Z","timestamp":1787279176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10668-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10668"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10668-6","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"95"}}